182 related articles for article (PubMed ID: 38031404)
1. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.
Chen C; Zhou R; Fu F; Xiao J
Eur Psychiatry; 2023 Nov; 66(1):e99. PubMed ID: 38031404
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Zhou J; Zheng Y; Xu B; Long S; Zhu LE; Liu Y; Li C; Zhang Y; Liu M; Wu X
BMC Med; 2024 Feb; 22(1):65. PubMed ID: 38355513
[TBL] [Abstract][Full Text] [Related]
3. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.
Dong S; Sun C
Front Endocrinol (Lausanne); 2022; 13():1032199. PubMed ID: 36583004
[TBL] [Abstract][Full Text] [Related]
4. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
Guirguis A; Chiappini S; Papanti P GD; Vickers-Smith R; Harris D; Corkery JM; Arillotta D; Floresta G; Martinotti G; Schifano F
Eur Neuropsychopharmacol; 2024 May; 82():82-91. PubMed ID: 38508100
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
Cao M; Pan C; Tian Y; Wang L; Zhao Z; Zhu B
Int J Clin Pharm; 2023 Jun; 45(3):689-697. PubMed ID: 36977858
[TBL] [Abstract][Full Text] [Related]
7. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
8. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
9. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Mansur RB; Rosenblat JD; Kwan ATH
Expert Opin Drug Saf; 2024 Jan; 23(1):47-55. PubMed ID: 38087976
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.
Yang Z; Lv Y; Yu M; Mei M; Xiang L; Zhao S; Li R
Front Pharmacol; 2022; 13():925377. PubMed ID: 36386208
[No Abstract] [Full Text] [Related]
11. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.
Zhao Z; Tang Y; Hu Y; Zhu H; Chen X; Zhao B
Ann Transl Med; 2021 Sep; 9(18):1482. PubMed ID: 34734034
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
Ruggiero R; Mascolo A; Spezzaferri A; Carpentieri C; Torella D; Sportiello L; Rossi F; Paolisso G; Capuano A
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399362
[TBL] [Abstract][Full Text] [Related]
14. Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.
Zhou Y; Chen M; Liu L; Chen Z
Diabetes Metab Syndr Obes; 2022; 15():155-163. PubMed ID: 35046686
[TBL] [Abstract][Full Text] [Related]
15. The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system.
Yang Z; Yu M; Mei M; Chen C; Lv Y; Xiang L; Li R
Nutr Metab Cardiovasc Dis; 2022 Feb; 32(2):504-510. PubMed ID: 34895802
[TBL] [Abstract][Full Text] [Related]
16. The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase.
Battini V; Van Manen RP; Gringeri M; Mosini G; Guarnieri G; Bombelli A; Pozzi M; Nobile M; Radice S; Clementi E; Carnovale C
Front Pharmacol; 2023; 14():1128387. PubMed ID: 36873988
[No Abstract] [Full Text] [Related]
17. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.
Fadini GP; Sarangdhar M; Avogaro A
BMJ Open Diabetes Res Care; 2018; 6(1):e000475. PubMed ID: 29449951
[TBL] [Abstract][Full Text] [Related]
18. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.
Xiong S; Gou R; Liang X; Wu H; Qin S; Li B; Luo C; Chen J
Diabetes Ther; 2024 May; ():. PubMed ID: 38776037
[TBL] [Abstract][Full Text] [Related]
19. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
20. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Gastaldon C; Raschi E; Kane JM; Barbui C; Schoretsanitis G
Psychother Psychosom; 2021; 90(1):41-48. PubMed ID: 32854103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
